Immunogenicity and Efficacy of the Live Attenuated, Recombinant Chikungunya Virus Vaccine MV-CHIK in Non Human Primates

Project: Research project

Project Details

StatusFinished
Effective start/end date2/1/16 → 11/1/17

Funding

  • Themis Bioscience GmbH: $268,452.36